|
|||||
|
|
The role of HSP27 in the development of drug resistance of gastrointestinal malignancies: Current status and perspectives |
|
| Authors: | Atena Soleimani Mohammad Jalili-Nik Amir Avan Gordon A. Ferns Majid Khazaei Seyed Mahdi Hassanian |
| Affiliation: | 1. Department of Clinical Biochemistry, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran Student Research Committee, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran Atena Soleimani and Mohammad Jalili-Nik made equal contributions to this study.;2. Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran;3. Division of Medical Education, Brighton & Sussex Medical School, University of Brighton, Brighton, UK;4. Department of Clinical Biochemistry, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran |
| Abstract: | Heat-shock protein 27 (HSP27) is a chaperone molecule that plays a critical role in the refolding and activity of several proteins responsible for cancer cell drug toxicity. Upregulation of HSP27 is associated with decreased drug sensitivity as well as poorer survival in gastrointestinal (GI) malignancies. It is, therefore, possible that HSP27 may be of value in the assessment of prognostic and therapeutic efficacy in the treatment of GI cancers. Pharmacological and biological inhibitors of HSP27 enhance tumor cell chemosensitivity. This review summarizes the potential role of HSP27 in chemotherapy drug resistance and the therapeutic potential of HSP27 inhibitors as a novel strategy in the treatment of GI cancers. |
| Keywords: | drug resistance gastrointestinal malignancies heat-shock protein 27 survival |